Personalized tumor neoantigen (TSA)

Personalized tumor neoantigens are unique, non-self peptides derived from somatic mutations—such as single nucleotide variants, frameshifts, or chromosomal rearrangements—within a patient's specific tumor genome (Schumacher & Schreiber, 2015; Science). Unlike tumor-associated antigens, these neoantigens are not expressed in healthy tissues, allowing them to bypass central thymic tolerance and elicit robust, high-affinity T-cell responses with a low risk of autoimmune cross-reactivity (Sahin et al., 2017; Nature). These targets are identified using a combination of whole-exome sequencing and bioinformatic algorithms that predict the immunogenicity and MHC-binding affinity of identified mutations for a specific patient (Ott et al., 2017; Nature). In therapeutic contexts, they serve as the foundation for individualized cancer vaccines and adoptive T-cell therapies designed to focus the immune system's cytotoxic activity exclusively on malignant cells. While highly specific, the clinical application of neoantigen-targeting agents faces challenges related to complex manufacturing logistics and the potential for tumor progression during the production period (NCI, 2023).

Other names

Tumor-specific antigen (TSA)NeoepitopeMutation-derived antigenPrivate neoantigenTumor-specific neoantigen

Personalized tumor neoantigens act as high-affinity targets for the immune system by presenting unique, non-self peptide sequences on MHC molecules, which are then recognized by neoantigen-specific CD4+ and CD8+ T cells to trigger tumor-specific lysis (Schumacher & Schreiber, 2015; Science). Individualized therapies such as mRNA or peptide vaccines work by priming and expanding these T-cell populations to enhance the endogenous anti-tumor response (Ott et al., 2017; Nature).